Global Budesonide
Inhaler Market, by Product Type (Inhalants and Nebulizer), by Dosage
(Aerosols, Dry Powder, Suspension, and Sprays), by Strength (0.25mg, 0.5mg, and
1.0mg), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online
Pharmacy), and By Region (North America, Latin America, Europe, Asia Pacific,
Middle East, and Africa) was valued at US$
4.85 billion in 2017, and is projected to exhibit a CAGR of 5.8% over
the forecast period (2018 - 2026).
Key players in the market are
focused on developing generics version of budesonide inhaler in affordable
prices and in various forms such as dry powder, aerosols, suspensions or spray
for asthma patients. Increasing number of regulatory approvals for generic
versions of budesonide inhaler is a major factor driving growth of the
budesonide inhaler market. For instance, in 2018, Lupin received approval for
its budesonide inhalation suspension 0.5/2ml single dose ampules from the
U.S.FDA to market generic versions AstraZeneca’s Pulmicort Respules. It is
indicated for the maintenance treatment of asthma and as prophylactic therapy
in children 12 months to 8 years of age.
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/2551
Moreover, key manufacturers are
also focused on developing new combinations of budesonide inhaler with other
drugs to enhance their market share. Budesonide can be made in combination with
formoterol. In September 2016, Orion Corporation announced that it has entered
into a collaboration agreement with Menarini Group for the co-marketing of
budesonide-formoterol Easyhaler combination product in Germany, Italy, Spain,
and Portugal. Budesonide-formoterol Easyhaler is an inhaled combination product
indicated for asthma and chronic obstructive pulmonary disease (COPD). In this
formulation, budesonide acts as an anti-inflammatory agent and formoterol acts
as a long-acting bronchodilator. The product is available under the brand name
Bufomix Easyhaler in most of the European countries.
Browse 21 Market Data Tables and
19 Figures spread through 149 Pages and in-depth TOC on "Global Budesonide
Inhaler Market, by Product Type (Inhalants and Nebulizer), by Dosage (Aerosols,
Dry Powder, Suspension, and Sprays), by Strength (0.25mg, 0.5mg, and 1.0mg), by
Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy),
and By Region (North America, Latin America, Europe, Asia Pacific, Middle East,
and Africa) - Global Forecast to 2026" To know the latest trends and
insights related to budesonide inhaler market.
Browse Research
Report: https://www.coherentmarketinsights.com/market-insight/budesonide-inhaler-market-2551
Key Takeaways of the Budesonide
Inhaler Market:
The global budesonide inhaler
market is expected to witness a CAGR of 5.8% during the forecast period
(2018–2026), owing to increasing number of regulatory approvals for generic
versions of budesonide inhaler
Among product type, the inhalant
segment is expected to hold major revenue share in the market over the forecast
period.
Key players in the market are
focused on developing generic versions of budesonide inhaler for asthma and
COPD, which is expected to drive growth of the inhalant segment in the market.
For instance, in 2017, Cipla Ltd. received final approval for Budesonide
Inhalation Suspension, from the U.S. FDA to market a generic version of
AstraZeneca's Pulmicort Respules.
Major players operating in the
global budesonide inhaler market include, Pfizer Inc., Cipla Limited, Lupin
Limited, Cosmo Pharmaceuticals, Takeda Pharmaceutical Company Ltd., Manus
Aktteva Biopharma LLP, Abbott Laboratories, Lunan Better Pharmaceutical,
Novartis International AG (Sandoz), Mylan N.V., Skyepharma, AstraZeneca Plc.,
Chiesi Farmaceutici S.p.A, Orion Corporation, Santarus Inc., Synmosa Biopharma
Corporation, and Shanghai Sine Pharmaceutical Laboratories Co. Ltd.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/2551
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN
: +050-5539-1737
No comments:
Post a Comment